阿里巴巴-W(09988.HK)擬發行約120億港元零息可交換債券
格隆匯7月3日丨阿里巴巴-W(09988.HK)公吿,公司宣佈擬發行一項可交換債券,將參考阿里巴巴健康信息技術有限公司在香港聯交所上市的普通股(HKEX:00241)("阿里健康股份")。在市場及其他條件允許的情況下,公司擬發行本金總額為約120億港元、2032年到期的零息可交換債券。債券發行將依據《1933年美國證券法》及其修訂版項下的S條例,以私募方式向若干非美國人士於美國境外進行離岸交易。
債券發行後,債券將構成阿里巴巴集團無擔保及非次級債務。債券不會產生定期利息。債券將於2032年7月9日到期,除非根據債券條款於該日期前被提前贖回、回購或交換。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.